Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Matcheri S Keshavan, M.D.

Co-Author

This page shows the publications co-authored by Matcheri Keshavan and Alan Francis.
Connection Strength

3.535
  1. Callosal Abnormalities Across the Psychosis Dimension: Bipolar Schizophrenia Network on Intermediate Phenotypes. Biol Psychiatry. 2016 10 15; 80(8):627-35.
    View in: PubMed
    Score: 0.664
  2. Reduced subicular subdivisions of the hippocampal formation and verbal declarative memory impairments in young relatives at risk for schizophrenia. Schizophr Res. 2013 Dec; 151(1-3):154-7.
    View in: PubMed
    Score: 0.569
  3. Alterations in the cerebral white matter of genetic high risk offspring of patients with schizophrenia spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10; 40:187-92.
    View in: PubMed
    Score: 0.525
  4. Abnormalities of the corpus callosum in non-psychotic high-risk offspring of schizophrenia patients. Psychiatry Res. 2011 Jan 30; 191(1):9-15.
    View in: PubMed
    Score: 0.467
  5. Medial temporal lobe structures and hippocampal subfields in psychotic disorders: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. JAMA Psychiatry. 2014 Jul 01; 71(7):769-77.
    View in: PubMed
    Score: 0.149
  6. Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy. Schizophr Res. 2013 Aug; 148(1-3):59-66.
    View in: PubMed
    Score: 0.139
  7. Alterations in brain structures underlying language function in young adults at high familial risk for schizophrenia. Schizophr Res. 2012 Oct; 141(1):65-71.
    View in: PubMed
    Score: 0.131
  8. A broad cortical reserve accelerates response to cognitive enhancement therapy in early course schizophrenia. Schizophr Res. 2011 Aug; 130(1-3):123-9.
    View in: PubMed
    Score: 0.121
  9. Progressive alterations of the auditory association areas in young non-psychotic offspring of schizophrenia patients. J Psychiatr Res. 2011 Feb; 45(2):205-12.
    View in: PubMed
    Score: 0.113
  10. Gray matter loss in young relatives at risk for schizophrenia: relation with prodromal psychopathology. Neuroimage. 2011 Jan; 54 Suppl 1:S272-9.
    View in: PubMed
    Score: 0.112
  11. Grey matter and cognitive deficits in young relatives of schizophrenia patients. Neuroimage. 2011 Jan; 54 Suppl 1:S287-92.
    View in: PubMed
    Score: 0.111
  12. Premorbid cognitive deficits in young relatives of schizophrenia patients. Front Hum Neurosci. 2010; 3:62.
    View in: PubMed
    Score: 0.111
  13. Do inter-regional gray-matter volumetric correlations reflect altered functional connectivity in high-risk offspring of schizophrenia patients? Schizophr Res. 2010 May; 118(1-3):62-8.
    View in: PubMed
    Score: 0.110
  14. Verbal fluency deficits and altered lateralization of language brain areas in individuals genetically predisposed to schizophrenia. Schizophr Res. 2009 Dec; 115(2-3):202-8.
    View in: PubMed
    Score: 0.108
  15. Hippocampal volume is reduced in schizophrenia and schizoaffective disorder but not in psychotic bipolar I disorder demonstrated by both manual tracing and automated parcellation (FreeSurfer). Schizophr Bull. 2015 Jan; 41(1):233-49.
    View in: PubMed
    Score: 0.036
  16. Gray matter volume as an intermediate phenotype for psychosis: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry. 2013 Nov; 170(11):1285-96.
    View in: PubMed
    Score: 0.036
  17. Brain gray matter phenotypes across the psychosis dimension. Psychiatry Res. 2012 Oct 30; 204(1):13-24.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.